References
- Al-Nassir WN, Sethi AK, Li Y, et al. (2008). Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 52:2403–6
- Anosova NG, Brown AM, Li L, et al. (2013). Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters. J Med Microbiol 62:1394–404
- Atyabi F, Inanloo K, Dinarvand R. (2005). Bovine serum albumin–loaded pectinate beads as colonic peptide delivery system: preparation and in vitro characterization. Drug Deliv 12:367–75
- Barra-Carrasco J, Olguín-Araneda V, Plaza-Garrido A, et al. (2013). The Clostridium difficile exosporium cysteine (CdeC)-rich protein is required for exosporium morphogenesis and coat assembly. J Bacteriol 195:3863–75
- Chaparro-Rojas F, Mullane KM. (2013). Emerging therapies for Clostridium difficile infection – focus on fidaxomicin. Infect Drug Resist 6:41–53
- DuPont HL. (2011). The search for effective treatment of Clostridium difficile infection. N Engl J Med 364:473–5
- Eaton SR, Mazuski JE. (2013). Overview of severe Clostridium difficile infection. Crit Care Clin 29:827–39
- Freeman J, Stott J, Baines SD, et al. (2005). Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 56:988–9
- Genisyuerek S, Papatheodorou P, Guttenberg G, et al. (2011). Structural determinants for membrane insertion, pore formation and translocation of Clostridium difficile toxin B. Mol Microbiol 79:1643–54
- Guo G, Xing P, Liu H, et al. (2013). The expression of C. difficile toxin A C-terminal domain and preparation of IgY antibody. J Militar Med 196:676–80
- Hansen P, Scoble JA, Hanson B, et al. (1998). Isolation and purification of immunoglobulins from chicken eggs using thiophilic interaction chromatography. J Immunol Methods 215:1–7
- Hawkey PM, Marriott C, Liu WE, et al. (2013). Molecular epidemiology of Clostridium difficile infection in a major Chinese hospital: an underrecognized problem in Asia? J Clin Microbiol 51:3308–13
- Kelly CP, Kyne L. (2011). The host immune response to Clostridium difficile. J Med Microbiol 60:1070–9
- Kink JA, Williams JA. (1998). Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66:2018–25
- Koenigsknecht MJ, Young VB. (2013). Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: current promise and future needs. Curr Opin Gastroenterol 29:628–32
- Lima AA, Lyerly DM, Wilkins TD, et al. (1988). Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun 56:582–8
- Lowy I, Molrine DC, Leav BA, et al. (2010). Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197–205
- O'Donoghue C, Kyne L. (2011). Update on Clostridium difficile infection. Curr Opin Gastroenterol 27:38–47
- Ramasamy T, Ruttala HB, Shanmugam S, et al. (2013). Eudragit-coated aceclofenac-loaded pectin microspheres in chronopharmacological treatment of rheumatoid arthritis. Drug Deliv 20:65–77
- Rao K, Micic D, Chenoweth E, et al. (2013). Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults. J Am Geriatr Soc 61:1738–42
- Roberts A, McGlashan J, Al-Abdulla I, et al. (2011). Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infect Immun 80:875–82
- Søes LM, Holt HM, Böttiger B, et al. (2013). Risk factors for Clostridium difficile infection in the community: a case–control study in patients in general practice, Denmark, 2009–2011. Epidemiol Infect 27:1–12
- Tian JH, Fuhrmann SR, Kluepfel-Stahl S, et al. (2012). A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 30:4249–58
- Tsai SW, Yu DS, Tsao SW, et al. (2013). Hyaluronan-cisplatin conjugate nanoparticles embedded in Eudragit S100-coated pectin/alginate microbeads for colon drug delivery. Int J Nanomed 8:2399–407
- Voelker R. (2012). Study: vast majority of C. difficile infections occur in medical settings. JAMA 307:1356